Adicet Bio
ACET
45 hedge funds and large institutions have $108M invested in Adicet Bio in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
15% more funds holding
Funds holding: 39 → 45 (+6)
1% more capital invested
Capital invested by funds: $107M → $108M (+$1.02M)
0.01% more ownership
Funds ownership: 0.37% → 0.38% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$3.27M |
| 2 |
Jennison Associates
New York
|
+$2.76M |
| 3 |
DAM
Deltec Asset Management
New York
|
+$2.64M |
| 4 |
SCM
Segantii Capital Management
Hong Kong
|
+$1.19M |
| 5 |
AG
Artal Group
Luxembourg
|
+$961K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.82M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$525K |
| 3 |
AC
Ascend Capital
Orinda,
California
|
-$414K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$191K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$120K |
ACET Hedge Fund Activity: Q2 2018 in Review
45 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q2 2018, worth a combined $108M — up 0.95% from $107M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ACET positions and 6 closed out — a net gain of 6 holders — while 14 added to existing stakes and 8 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $3.27M. The largest seller was Fidelity Investments, cutting an estimated $8.82M.
- 45 institutional investors held Adicet Bio (ACET) as of Q2 2018, up from 39 in Q1 2018.
- Funds reported $108M of Adicet Bio stock for Q2 2018, up 0.95% quarter-over-quarter.
- 12 funds opened new Adicet Bio positions in Q2 2018 and 6 closed out, a net change of +6 holders.
- The largest Adicet Bio buyer in Q2 2018 was Baillie Gifford & Co, an estimated $3.27M added.
- The largest Adicet Bio seller in Q2 2018 was Fidelity Investments, an estimated $8.82M sold.
Based on aggregated 13F filings for Q2 2018.